Experimental treatments are never without their downsides. Immunotherapy drugs like Opdivo, Keytruda, or Tecentriq are no different. Although some patients have experienced remarkable results, some are not so fortunate.
Immunotherapy drugs are often called checkpoint inhibitors. The term is derived from the nature of cancer cells which can mask their identity using proteins so that they appear normal to the body. This masking prevents the body from using the immune system to combat the cancer. Immunotherapy drugs counter this and allow the body to fight the cancerous cells.
In some cases, researchers have found that the checkpoint inhibitor drugs are causing tumors to grow more rapidly. In other cases, the immunotherapy has had no impact. Given the high cost of the treatments and the certainty of a fatal outcome, the cure is worse than the disease in these cases.
In another promising treatment known as CAR T-cell therapy, physicians remove certain cells from the patient then reengineer them to battle the cancer. Despite the potential this treatment offers, some patients experience swelling of the brain. This cerebral edema led to four fatalities in clinical trials in 2016.
Finally, in some cases the checkpoint inhibitors have allowed the body to wrongfully attack healthy cells in the body. This naturally resulted in serious complications otherwise unrelated to the cancer.
Because of the potential for successful treatment of cancers such as mesothelioma, research continues. Every researcher understands that no potential treatment is without setbacks. The three major checkpoint inhibitor drugs Opdivo, Keytruda, and Tecentriq are just the beginning.
University Hospital in Basel, Switzerland demonstrated the potential of these drugs in patients with non-small cell lung cancer. The study found that when patients were treated with PD-1/PD-L1 checkpoint inhibitors prior to receiving chemotherapy, they were 30 percent more likely to respond well in the overall regimen. Thus, researchers are looking more closely at not only the combined approach, but also the strategic use of timing in the fight.
Philadelphia mesothelioma lawyers at Brookman, Rosenberg, Brown & Sandler are dedicated to helping families throughout Pennsylvania and New Jersey fight those who are responsible for their asbestos exposure. To schedule a free consultation, contact us online or call 800-369-0899 or 215-569-4000.
Occupational hazards are associated with working at an oil refinery, from the risk of fires or explosions to being exposed…
The recurring pattern of poor communication plagues both the City of Atlantic City and the Atlantic City Public Schools system…
Asbestos shingle siding dates back to 1907, and the National Board of Fire Underwriters later endorsed it for its resistance…
Mesothelioma is an incurable disease that will have an immeasurable impact on both the person who was diagnosed and their…
Depending on the kind of mesothelioma you have and whether it has progressed, treatment options may alleviate symptoms and extend…
Mesothelioma is an aggressive form of cancer that is caused by exposure to asbestos. In most cases, mesothelioma affects people…